MetaCap

Artivion Inc. (AORT)

NYSE: AORTHealth CareMedical/Dental InstrumentsUSD

18.16-0.37 (-2.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AORT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$886.02M
EPS (TTM)
-$0.36
Ex-dividend date
Dec 9, 2015
52-week range
18.12 – 48.25
Day range
18.13 – 18.93
Volume / Avg
642.10K / 671.97K
Beta
—

52-week range

$18.12$48.25

AORT stock today

On Nov 20, AORT ended the session at $18.16, shedding $0.37 (2.00%), versus the S&P 500's 3.70% decline. At this level, AORT sits near the bottom of its 52-week range of $18.12 to $48.25: 62.4% below the high, set on Dec 17, 2025 and 0.2% above the low. AORT is down 60.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 59.8%.

Artivion has posted a net loss over the last twelve months (EPS of -$0.36), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Artivion

Company profile

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system.

Industry
Medical/Dental Instruments
CEO
Mr. James Patrick Mackin
Headquarters
Kennesaw, GA
Employees
1,800

Financial highlights

Full financials

In fiscal 2025, Artivion generated $441.3 million in revenue, up 13.6% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $9.8 million, for a net margin of 2.2% versus a median of -6.1% in the prior 5 years. Gross margin was 64.4% (up from 64.0%) and operating margin 7.6%.

Artivion annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$441.33M$388.54M$354.00M$313.79M$298.84M
Growth+13.59%+9.75%+12.82%+5.00%+18.01%
Net income$9.77M$-13.36M$-30.69M$-19.19M$-14.83M
EPS (diluted)$0.21$-0.32$-0.75$-0.48$-0.38

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$38.47+111.84%

  • Strong buy 2
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $30.00High $45.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.16 vs $0.11
Surprise
+45.45%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$0.03
Ex-dividend date
Dec 9, 2015

AORT news

All AORT news

Artivion peers

Health Care sector
AORT peer companies
CompanyPrice% ChgMarket capCompare
KIDSOrthoPediatrics Corp.31.74-2.37%$828.75Mvs AORT
VVVVvVARDIS Holding AG Class A14.55-3.00%$770.91Mvs AORT
SGPSpyGlass Pharma Inc.30.43-1.14%$1.02Bvs AORT
ATECAlphatec Holdings Inc.6.68-3.19%$1.02Bvs AORT
IARTIntegra LifeSciences Holdings Corporation13.25-2.21%$1.03Bvs AORT
IRMDiRadimed Corporation81.02-0.30%$1.04Bvs AORT
BBNXBeta Bionics Inc.13.36+0.30%$726.34Mvs AORT
SIBNSI-BONE Inc.23.73-0.08%$1.07Bvs AORT

Indexes, lists and sector

Artivion stock FAQ

What is Artivion's stock price today?

AORT last traded at $18.16 as of Nov 20, 4:00 PM EST, down 2.00% on the day. Prices are delayed at least 15 minutes.

Does Artivion pay a dividend?

Yes. Artivion pays $0.00 per share annually. The most recent dividend of $0.03 had an ex-dividend date of Dec 9, 2015.

Who is Artivion's CEO?

Mr. James Patrick Mackin is the chief executive officer of Artivion Inc., which has about 1,800 employees.

Has AORT ever split its stock?

Yes. The most recent AORT stock split was a 3-for-2 split on Dec 28, 2000, one of 2 splits on record.

What is the AORT 52-week high?

The 52-week high for AORT is $48.25 and the 52-week low is $18.12. The stock is currently 62.4% below its high.

Compare AORT